Table 3.

Prognostic significance of sEV-derived ncRNAs in PDAC

Reference	Sample	sEV Isolation	Normalization	ncRNA	Tumor type	Patients by UICC stage					Effect	UVA	MVA
						I	IIA	IIB	III	IV
Mikamori et al. [127]	Plasma	EQ	cel-miR-39	miR-155	PDAC	23			–	–	High expression correlated with shorter DFS	✓	–
Takahasi et al. [175]	Plasma	UC	miR-16a	miR-451a	PDAC	7	43		–	–	High expression correlated with shorter DFS/OS	✓	✓
Goto et al. [145]	Serum	EQ	not specified	miR-21	all PC	2	7	4	5	14	High expression correlated with shorter OS (344 days vs. 846 days)	✓	✓
Li et al. [53]	Plasma	EQ	RNU6, β-actin mRNA	lncSox2ot	PDAC	28		28			High expression correlated with shorter OS (12 months vs. 15 months)	✓	✓
Li et al. [47]	Plasma	EQ	RNU6, β-actin mRNA	circPDE8A	PDAC	47		40			High expression correlated with shorter OS (13 months vs. 16 months)	✓	✓
Wang et al. [84]	Serum	TEI	cel-miR-39	miR-301a-3p	all PC	20			30		High expression correlated with shorter OS	✓	✓
Li et al. [57]	Plasma	TEI	not specified	circIARS	PDAC	42		39			High expression correlated with shorter OS (11 months vs. 16 months)	✓	✓
Li et al. [49]	Plasma	EQ	not specified	miR-222	PDAC	39		34			High expression correlated with shorter OS (10 months vs. 17 months)	✓	✓
Kawamura et al. [161]	PVB	UC	cel-miR-39, miR-16	miRs 21, 451a, 4525	PDAC	4	27	24	–	–	High expression correlated with shorter DFS/OS	✓	✓
Reese et al. [155]	Serum	UC	cel-miR-39	miR-200c	PDAC	–	4	14	22	16	High expression correlated with shorter OS (miR-200c: 11 months vs. 18 months) (miR-200b: 9 months vs. 18 months)	✓	–
				miR-200b								✓	✓
Guo et al. [116]	Serum	EQ	β-actin	lncUCA1	all PC	20			26		High expression correlated with shorter OS	✓	–
Shao et al	Serum	EQ	cel-miR-39	miR-483-3p	PDAC	18	37		6	2	High expression correlated with shorter OS	✓	✓
Nishiwada et al. [176]	Plasma/Serum	TEI	miR-16	6 miR-panel (130b-5p, 133a-3p, 195-5p, 432-5p, 1229-3p, 1273f)	PDAC	3	8	14	–	–	Discovery cohort “high risk” correlated with shorter RfS	✓	✓
						9	12	33	26	2	Training cohort “high risk” correlated with shorter RfS	✓	✓
						3	22	31	1	–	Validation cohort I (did not receive NAT) “high risk” correlated with shorter RfS	✓	✓
						10	21	13	2	–	Validation cohort II (received NAT) “high risk” correlated with shorter RfS	✓	✓

cel, Caenorhabditis elegans; DFS, disease-free survival; EQ, ExoQuick (SystemBiosciences); MVA, multivariate survival analysis; n, number of patients; NAT, neoadjuvant therapy; OS, overall survival; PC, pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PVB, portal vein blood; TEI, Total Exosome Isolation Kit (ThermoFisher); UC, ultracentrifugation; UVA, univariate survival analysis